The new paradigm of hepatitis C therapy: Integration of oral therapies into best practices

N. H. Afdhal, S. Zeuzem, R. T. Schooley, D. L. Thomas, J. W. Ward, A. H. Litwin, H. Razavi, L. Castera, T. Poynard, A. Muir, S. H. Mehta, L. Dee, C. Graham, D. R. Church, A. H. Talal, M. S. Sulkowski, I. M. Jacobson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.

Original languageEnglish (US)
Pages (from-to)745-760
Number of pages16
JournalJournal of Viral Hepatitis
Volume20
Issue number11
DOIs
StatePublished - 2013

Fingerprint

Hepatitis C
Practice Guidelines
Hepacivirus
Chronic Hepatitis C
Centers for Disease Control and Prevention (U.S.)
Therapeutics
Advisory Committees
Interferons
Antiviral Agents
Communicable Diseases
Primary Health Care
Parturition
Biopsy
Liver

Keywords

  • diagnosis
  • directly acting antiviral agents
  • health services
  • hepatitis C
  • pharmacoeconomics

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Afdhal, N. H., Zeuzem, S., Schooley, R. T., Thomas, D. L., Ward, J. W., Litwin, A. H., ... Jacobson, I. M. (2013). The new paradigm of hepatitis C therapy: Integration of oral therapies into best practices. Journal of Viral Hepatitis, 20(11), 745-760. https://doi.org/10.1111/jvh.12173

The new paradigm of hepatitis C therapy : Integration of oral therapies into best practices. / Afdhal, N. H.; Zeuzem, S.; Schooley, R. T.; Thomas, D. L.; Ward, J. W.; Litwin, A. H.; Razavi, H.; Castera, L.; Poynard, T.; Muir, A.; Mehta, S. H.; Dee, L.; Graham, C.; Church, D. R.; Talal, A. H.; Sulkowski, M. S.; Jacobson, I. M.

In: Journal of Viral Hepatitis, Vol. 20, No. 11, 2013, p. 745-760.

Research output: Contribution to journalArticle

Afdhal, NH, Zeuzem, S, Schooley, RT, Thomas, DL, Ward, JW, Litwin, AH, Razavi, H, Castera, L, Poynard, T, Muir, A, Mehta, SH, Dee, L, Graham, C, Church, DR, Talal, AH, Sulkowski, MS & Jacobson, IM 2013, 'The new paradigm of hepatitis C therapy: Integration of oral therapies into best practices', Journal of Viral Hepatitis, vol. 20, no. 11, pp. 745-760. https://doi.org/10.1111/jvh.12173
Afdhal, N. H. ; Zeuzem, S. ; Schooley, R. T. ; Thomas, D. L. ; Ward, J. W. ; Litwin, A. H. ; Razavi, H. ; Castera, L. ; Poynard, T. ; Muir, A. ; Mehta, S. H. ; Dee, L. ; Graham, C. ; Church, D. R. ; Talal, A. H. ; Sulkowski, M. S. ; Jacobson, I. M. / The new paradigm of hepatitis C therapy : Integration of oral therapies into best practices. In: Journal of Viral Hepatitis. 2013 ; Vol. 20, No. 11. pp. 745-760.
@article{aee131b69bf04276b5de577c6824b123,
title = "The new paradigm of hepatitis C therapy: Integration of oral therapies into best practices",
abstract = "Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.",
keywords = "diagnosis, directly acting antiviral agents, health services, hepatitis C, pharmacoeconomics",
author = "Afdhal, {N. H.} and S. Zeuzem and Schooley, {R. T.} and Thomas, {D. L.} and Ward, {J. W.} and Litwin, {A. H.} and H. Razavi and L. Castera and T. Poynard and A. Muir and Mehta, {S. H.} and L. Dee and C. Graham and Church, {D. R.} and Talal, {A. H.} and Sulkowski, {M. S.} and Jacobson, {I. M.}",
year = "2013",
doi = "10.1111/jvh.12173",
language = "English (US)",
volume = "20",
pages = "745--760",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The new paradigm of hepatitis C therapy

T2 - Integration of oral therapies into best practices

AU - Afdhal, N. H.

AU - Zeuzem, S.

AU - Schooley, R. T.

AU - Thomas, D. L.

AU - Ward, J. W.

AU - Litwin, A. H.

AU - Razavi, H.

AU - Castera, L.

AU - Poynard, T.

AU - Muir, A.

AU - Mehta, S. H.

AU - Dee, L.

AU - Graham, C.

AU - Church, D. R.

AU - Talal, A. H.

AU - Sulkowski, M. S.

AU - Jacobson, I. M.

PY - 2013

Y1 - 2013

N2 - Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.

AB - Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.

KW - diagnosis

KW - directly acting antiviral agents

KW - health services

KW - hepatitis C

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84885444012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885444012&partnerID=8YFLogxK

U2 - 10.1111/jvh.12173

DO - 10.1111/jvh.12173

M3 - Article

C2 - 24168254

AN - SCOPUS:84885444012

VL - 20

SP - 745

EP - 760

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 11

ER -